Tag Archive for: RNA-based

Versameb Announces Management Update

PRESS RELEASE | Basel, Switzerland, January 8, 2021

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, announces the appointment of Dr Klaas Zuideveld as Chief Executive Officer (CEO). Prof Friedrich Metzger will move back to the role of Chief Scientific Officer (CSO) to focus on developing Versameb’s innovative VERSagile RNA platform to enhance and combine therapeutic protein expression and cellular targeting, optimizing and tailoring first-in-class RNA therapeutics for hard to treat diseases.

Read more

Versameb raises CHF 6 million and strengthens team to advance its VERSagile technology platform towards clinical trials

PRESS RELEASE | Basel, Switzerland, July 15, 2020

Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective May 1 to advance its lead molecule into clinical development. Versameb is engaged in the discovery and development of next-generation RNA-based drugs using its proprietary VERSagile technology platform.

Read more

Versameb raises CHF 6.4 million in Seed C round and strengthens the team

PRESS RELEASE | Basel, Switzerland, October 17, 2019

Versameb AG, a Swiss biopharmaceutical company, announced today the successful closing of a CHF 6.4 million Seed C financing round, bringing the total capital raised to date to CHF 11.8 million. Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.

Read more

Versameb raises CHF 5.3 million for the development of mRNA therapies in regenerative medicine

PRESS RELEASE | Basel, December 18, 2018

Versameb AG, a Swiss biopharmaceutical company, announced today the successful closing of a Seed B financing round, bringing the total capital raised to date to CHF 5.3 millions. Versameb AG is developing a technology platform for transformative therapies, focusing on regenerative medicine through the local application of messenger ribonucleic acid (mRNA).

Read more